REDNVIA   Report issue

For profit Phase 4
Founded: Seoul Korea, Republic of (2019)

Organization Overview

First Clinical Trial
2020
NCT04521452
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

REDNVIA | REDNVIA Co., Ltd.

Active Ingredients

Drugs in Phase 4 Trials (1)

evogliptin (Suganon) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease Progression (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 1